Ventricular tachycardia future or investigational therapies: Difference between revisions
Hudakarman (talk | contribs) |
Hudakarman (talk | contribs) |
||
| Line 4: | Line 4: | ||
== Overview == | == Overview == | ||
Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo 40. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 22:22, 6 March 2020
|
Ventricular tachycardia Microchapters |
|
Differentiating Ventricular Tachycardia from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Ventricular tachycardia future or investigational therapies On the Web |
|
FDA on Ventricular tachycardia future or investigational therapies |
|
CDC onVentricular tachycardia future or investigational therapies |
|
Ventricular tachycardia future or investigational therapies in the news |
|
Blogs on Ventricular tachycardia future or investigational therapies |
|
to Hospitals Treating Ventricular tachycardia future or investigational therapies |
|
Risk calculators and risk factors for Ventricular tachycardia future or investigational therapies |
Overview
Pharmacologic therapy for preventing VAs has yielded disappointing results in recent years. Therapy has been limited because of variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. As adjuvant suppressive therapy in patients with ICDs, amiodarone and sotalol have been shown to reduce the rate of recurrent VT (71% and 15–44%, respectively) when compared with beta-blockers or placebo 40. Current guidelines recommend pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation to prevent VT/VF recurrence and reducing ICD shocks